智通财经APP获悉，11月26日，中国国家药监局药品审评中心（CDE）网站最新公示，赛诺菲（Sanofi）(SNY.US)申报的度普利尤单抗注射液获批一项新的临床试验默示许可，拟开发用于治疗经外用药治疗控制不佳的中重度慢性单纯性苔藓成人患者。公开资料 ...

The Singapore facility is part of Sanofi's 900 million euro investment to develop two new EVFs globally over five years. The ...

Sanofi SA added a new plant in Singapore to make vaccines and other medicines, as the French pharmaceutical group seeks to ...

The 58,000 sq m plant – Sanofi’s second factory in Singapore – will produce vaccines and other biopharmaceutical products ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Sanofi's $595m Singapore facility, Modulus, leverages advanced technology for rapid, flexible vaccine production, bolstering ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

French company looks to rein in how it gives discounts in federal program designed to help hospitals that serve low-income ...

Sanofi's Chief Digital Officer Emmanuel Frenehard had a thought that he just couldn't shake: how can Sanofi extend the ...

Sanofi is the third company - along with J&J and Eli Lilly - to attempt to change the way it pays for medicines under the ...

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.